Evelo Biosciences Announces Positive Phase 2 Data
Positive Phase 2 Clinical Data with EDP1815 in Psoriasis that Confirm Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Diseases
Effective, Safe, Well Tolerated, Convenient and Affordable
Our product candidates are non-live single strains of microbes and extracellular vesicles that are room-temperature stable and can be taken orally. In a Phase 2 clinical trial, our lead product candidate was well tolerated and safety data was comparable to placebo.
SINTAX™: A NEWLY UNCOVERED AREA OF HUMAN BIOLOGY
Treatments for multiple diseases
SINTAX medicines have the potential to treat a range of inflammatory conditions, including psoriasis and atopic dermatitis, arthritic diseases, inflammatory bowel disorders, neuroinflammatory diseases, such as Parkinson’s, Alzheimer’s and dementia, and cardiovascular conditions and metabolic disease, such as obesity and diabetes.
Advancing our medicines to patients who need them
We are rapidly progressing our product candidates through research and clinical development in order to realize our vision of providing effective, safe, convenient, and affordable medicines to patients who need them.
Life as an Evelonian
We have an ambitious, passionate, and dedicated team who are driven to have a major impact on global healthcare.
As a company, we are committed to providing a phenomenal growth environment and opportunities for employees to realize their potential.
Stay in the Know
January 17, 2022
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases
January 4, 2022
Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts
December 14, 2021